Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073580 · ClinicalTrials.gov registry record · Phase 3
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 88
- Enrollment target
NCT00073580 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 88 participants.
The verdict
NCT00073580, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS) undergoing off-pump coronary artery bypass (OPCAB) surgery.
Interventions
- DRUG Angiomax (bivalirudin) anticoagulant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2003-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073580
The ClinicalTrials.gov registry entry for NCT00073580 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Angiomax (bivalirudin) anticoagulant is the first listed.
NCT00073580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073580 about?
NCT00073580 is a clinical study titled "Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)". The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS) undergoing off-pump coronary artery bypass (OPCAB) surgery.
What is the current status of trial NCT00073580?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 88 participants. The study started on 2003-10.
What interventions are being tested in trial NCT00073580?
The interventions under investigation include: Angiomax (bivalirudin) anticoagulant (DRUG).
Who is sponsoring clinical trial NCT00073580?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.